Evidence map›Paper›PMID 29078734›Full record

ArticleStem cells and development2017

Ovarian Cancer Stem Cells: Unraveling a Germline Connection.

Seema C Parte, Andrei Smolenkov, Surinder K Batra, Mariusz Z Ratajczak, Sham S Kakar

Abstract read
In one paragraph

Article in Stem cells and development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis.Advances in experimental medicine and biology · 2021
    Article
  6. DEAD-Box Helicase 4 (Ddx4)International journal of molecular sciences · 2020
    Article
  7. Stem Cells in Ovarian Cancer and Potential Therapies.Proceedings of stem cell research and oncogenesis · 2020
    Article
  8. Review
  9. Article
  10. Cellular consequences of arginine methylation.Cellular and molecular life sciences : CMLS · 2019
    Review
  11. Presence and role of stem cells in ovarian cancer.World journal of stem cells · 2019
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Seema C Parte1 Department of Physiology, University of Louisville , Louisville, Kentucky.
Andrei Smolenkov2 James Graham Brown Cancer Center, University of Louisville , Louisville, Kentucky.
Surinder K Batra3 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska.
Mariusz Z Ratajczak2 James Graham Brown Cancer Center, University of Louisville , Louisville, Kentucky.
Sham S Kakar1 Department of Physiology, University of Louisville , Louisville, Kentucky.
University of Louisville · USJames Graham Brown Foundation · USUniversity of Nebraska Medical Center · US

Funding

MIC-1 and its functional partners in prostate cancer racial disparityU01CA185148 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2015 to 2019
$1.6M
PTTG Role in Ovarian Tumorigenesis and MatastasisR01CA124630 · NCI · UNIVERSITY OF LOUISVILLE · PI KAKAR, SHAM S. · 2007 to 2011
$1.3M
NCI NIH HHS R01 CA124630NCI NIH HHS U01 CA185148
6 · The paper itself

Abstract

Ovarian cancer is most lethal among gynecological cancers with often fatal consequences due to lack of effective biomarkers and relapse, which propels ovarian cancer research into unique directions to establish solid targeted therapeutics. "Ovarian stem cells" expressing germline pluripotent markers serve as novel paradigm with potential to address infertility, menopause, and probably influence tumor initiation. Cancer stem cells (CSCs) pose vital role in tumor recurrence and hence it is extremely important to study them with respect to ovarian stem cells across various cancer stages and normal ovaries. Pluripotent (OCT4, NANOG, SOX2, SSEA1, and SSEA4), germline (IFITM3, VASA/DDX4), and cancer stem (CD44, LGR5) cell specific markers were characterized for protein and mRNA expression in tumor tissues to understand their distribution in the surface epithelium and ovarian cortex in benign, borderline, and high-grade malignant stages. To elucidate whether pluripotent ovarian germline stem cells and CSCs are common subset of stem cells in tumor tissues, VASA was colocalized with known pluripotent stem (OCT4, SSEA1, SSEA4) and CSC (CD44, LGR5) specific markers by confocal microscopy. Single, smaller spherical (≤5 μm), and larger elliptical fibroblast like (≥10 μm) cells (also in clusters or multiples) were detected implying probable functional behavioral significance of cells in tumor initiation and metastasis across various cancer stages. Cells revealed characteristic staining pattern in ovarian surface epithelium (OSE) and cortex regions exclusive for each marker. Co-expression studies revealed specific subpopulations existing simultaneously in OSE and cortex and that a dynamic hierarchy of (cancer) stem cells with germline properties prevails in normal ovaries and cancer stages. Novel insights into CSC biology with respect to ovarian and germline stem cell perspective were obtained. Understanding molecular signatures and distribution within ovarian tissue may enable identification of precise tumor-initiating CSC populations and signaling pathways thus improving their efficient targeting and strategies to prevent their dissemination causing fatal relapse.

Indexed as

AnimalsBiomarkers, TumorCell Transformation, NeoplasticEpitheliumFemaleGerm CellsHumansNeoplasm Recurrence, LocalNeoplastic Stem CellsOvarian NeoplasmsSignal TransductionBiomarkers, Tumorcancer stem cellsDDX4/VASAgermline stem cellsovarian cancerovarian stem cellsovarian surface epithelium

Identifiers

PMID29078734
PMCPMC5725638
OpenAlexW2765528115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.